Studies on left ventricular hypertrophy regression in arterial hypertension: A clear message for the clinician?

American Journal of Hypertension

Volumn 21, Issue 4, 2008, Pages 458-463

  Cuspidi, Cesare ^a,b   Esposito, Arturo ^b,c   Negri, Francesca ^b   Sala, Carla ^c,d   Masaidi, Meilikè ^c   Giudici, Valentina ^b   Zanchetti, Alberto ^d   Mancia, Giuseppe ^a,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Policlinico di Monza   (Italy)

^c MAGGIORE HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; ISRADIPINE; LISINOPRIL; LOSARTAN; MIBEFRADIL; NIFEDIPINE; NITRENDIPINE; PLACEBO; PRAZOSIN; RAMIPRIL; RILMENIDINE; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION;

EID: 41349093821     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2007.85     Document Type: Article

References (54)

1. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Study. N Engl J Med 1990; 322:1561-1566.
3. Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA, Castelli WP. Left ventricular mass and the risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA 1994; 272:33-36.
4. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A; APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20:1307-1314.
5. Schillaci G, de Simone G, Reboldi G, Porcellati C, Devereux RB, Verdecchia P. Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. J Hypertens 2002; 20:1519-1525.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
7. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15:1021-1028.
8. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1105.
9. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
10. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
11. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-899.
12. Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M. Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. J Cardiovasc Pharmacol 1995; 26:471-476.
13. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr, Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91:698-706.
14. Agabiti-Rosei E, Ambrosioni E, Dal Palù C, Muiesan ML, Zanchetti A. ACE-inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens 1995; 13:1325-1334.
15. Lièvre M, Guéret P, Gayet C, Roudaut R, Haugh MC, Delair S, Boissel JP. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension 1995; 25:92-97.
16. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95:2007-2014.
17. Papademetriou V, Gottdiener JS, Narayan P, Cushman WG, Zachariah PK, Gottdiener PS, Chase GA. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. J Am Coll Cardiol 1997; 30:1802-1808.
18. Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG. ACE-inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 1997; 12:945-951.
19. Scognamiglio R, Nosadini R, Marin M, Nisti S, Fasoli G, Palisi M, Frigato F, Virgili F, Carraro A, Crepaldi G. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients. Diabetes Care 1997; 20:1290-1297.
20. Beltman FW, Heesen WF, Smit AJ, May JF, De Graeff PA, Havinga TK, Schuurman FH, van der Veur E, Lie KI, Meyboom-de Jong B. Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press 1998; 7:109-117.
21. Tedesco MA, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S, Galzerano D, Iarussi D, Iacono A. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12:505-510.
22. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrok N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.
23. Gerritsen TA, Bak AA, Stolk RP, Jonker JJ, Grobbee DE. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. J Hypertens 1998; 16:689-696.
24. Höglund C, Cifkova R, Mimran A, Tenczer J, Watt A, Wilkins MR, Lindberg E. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. Cardiology 1998; 89:263-270.
25. Sadowski Z, Szwed H, Kuch-Wocial A, Kubasik A, Januszewicz W, Krupa-Wojciechowska B, Polak G, Stejfa M, Dvorak I, Blazovjech I, Dubai G, Simon K. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmedine: a double-blind, randomized, controlled (versus nifedipine) study. J Hypertens Suppl 1998; 16:S55-S62.
26. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998; 11:387-396.
27. Hernández D, Lacalzada J, Salido E, Linares J, Barragán A, Lorenzo V, Higueras L, Martín B, Rodríguez A, Laynez I, González-Posada JM, Torres A. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58:889-897.
28. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Guéret P, Karpov Y, De Leeuw PW, Palma-Gamiz JL, Pessina A, Motz W, Degaute JP, Chastang C. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg : the LIVE study. J Hypertens 2000; 18:1465-1475.
29. Avanza AC Jr, El Aouar LM, Mill JG. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq Bras Cardiol 2000; 74:103-117.
30. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, Fauchald P, Holdaas H. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001; 72:107-111.
31. Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van der Veur E, Schuurman FH, Meyboom-de Jong B, Crijns HJ. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19:303-309.
32. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlöf B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 2001; 104:1248-1254.
33. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Ohman KP, Osbakken MD, Ostergren J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176.
34. Heesen WF, Beltman FW, Smit AJ, May JF, de Graeff PA, Muntinga JH, Havinga TK, Schuurman FH, van der Veur E, Meyboom-de Jong B, Lie KI. Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. J Cardiovasc Pharmacol 2001; 37:512-521.
35. Black HR, Elliot WJ, Weber MA, Frishman WH, Strom JA, Liebson PR, Hwang CT, Ruff DA, Montoro R, De Quattro V, Zhang D, Schleman MM, Klibaner MI. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension 2001; 38:1118-1123.
36. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20:2293-2300.
37. De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002; 16:133-140.
38. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, Aurup P, Smith RD, Johansson M; For the REGAAL Study Investigators. Effect of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864.
39. Leenen FH, Myers MG, Joyner CD, Toal CB. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: nifedipine-GITS versus felodipine.ER versus enalapril. Can J Cardiol 2002; 18:1285-1293.
40. Gaudio C, Ferri FB, Giovannini M, Pannarale G, Puddu PE, Vittore A, Fera MS, Vizza CD, Fedele F. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003; 42:622-628.
41. Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE. Effect of irbesartan versus atenolol on left ventricular mass and voltage. Results of the CardioVascular Irbesartan Project. Hypertension 2004; 44:61-66.
42. de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, Romero R, De Leeuw PW, Hitzenberger G, Battegay E, Duprez D, Sever P, Safar M. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as first-line combination: the REASON echocardiographic study. Am J Hypertens 2004; 17:660-667.
43. Libhaber EN, Libhaber CD, Candy GP, Sliwa K, Kachope J, Ntombi M, Puane MO, Woodiwiss AJ, Norton GR, Essop MR, Sareli P. Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry. Am J Hypertens 2004; 17:428-432.
44. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43:2116-2023.
45. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared to atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
46. Dahlof B, Gosse P, Guéret P, Dubourg O, de Simone G, Schmieder R, Karpov Y, García-Puig J, Matos L, De Leeuw PW, Degaulte JP, Magometschnigg D. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23:2063-2070.
47. Agabiti-Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R, Hennig M, Baurecht H, Parati G, Mancia G, Zanchetti A; ELSA Echocardiographic Substudy Group. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005; 23:1091-1098.
48. Galzerano D, Tammaro P, del Viscovo L, Lama M, Galzerano A, Breglio R, Tuccillo B, Paolisso G, Caporosso P. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005; 18:1563-1569.
49. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006; 70:995-1000.
50. Iaccarino G, Izzo R, Trimarco V, Cipolletta E, Lanni F, Sorriento D, Iovino GL, Rozza F, De Luca N, Priante O, Di Renzo G, Trimarco B. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. Clin Pharmacol Ther 2006; 80:633-645.
51. de Simone G, Devereux RB, Maggioni AP, Gorini M, de Divitiis O, Verdecchia P; MAVI (Massa Ventricolare sinistra nell'Ipertensione) Study group. Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study. Am J Hypertens 2005; 18:1288-1293.
52. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
53. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
54. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43:731-738.